(28 Apr 2021) Camostat mesilate- did not affect time to clinical improvement

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial

https://doi.org/10.1016/j.eclinm.2021.100849

NCT04321096- 137 patients were assigned to receive camostat mesilate and 68 to placebo. Median time to clinical improvement was 5 days (interquartile range [IQR], 3 to 7) in the camostat group and 5 days (IQR, 2 to 10) in the placebo group (P = 0.31). The hazard ratio for 30-day mortality in the camostat compared with the placebo group was 0.82 (95% confidence interval [CI], 0.24 to 2.79; P = 0.75). The frequency of adverse events was similar in the two groups. Median change in viral load from baseline to day 5 in the camostat group was -0.22 log10 copies/mL (p <0.05) and -0.82 log10 in the placebo group (P <0.05). Under this protocol, camostat mesilate treatment was not associated with increased adverse events during hospitalization for Covid-19 and did not affect time to clinical improvement, progression to ICU admission or mortality.